Bio News
BlossomHill raised 213.3 billion won ($150 million) through its IPO. The company sold 9.375 million shares at $16 per share, more than initially planned. BlossomHill plans to allocate $70 million (approximately 99.5 billion won) of the proceeds to developing BH-30643, a treatment for non-small cell lung cancer.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
